|
Table of Contents
1. Report Overview
1.1 Overview of the World Market for Biosimilar Monoclonal Antibodies
1.2 Why You Should Read This Report
1.3 How This Study Delivers
1.4 Main Questions Answered by the Analysis
1.5 Who Is This Investigation For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Biosimilar Monoclonal Antibodies
2.1 Natural Antibodies: Key to the Immune System
2.2 From Serum Therapy to Monoclonal Antibodies (MAbs)
2.3 Humanising the MAb
2.4 Biologics (Biological Drugs) and Biosimilars
2.5 Why are Biosimilars in High Demand?
2.6 Considerations for the Development of Biosimilars
2.6.1 Biologics and Biosimilars Are Large, Complex Molecules
2.6.2 How Much a Concern is Immunogenicity?
2.7 Biosimilar Monoclonal Antibodies on the Market
3. World Market Prospects for Biosimilar Monoclonal Antibodies, 2015-2025
3.1 The World Market for Biosimilar Monoclonal Antibodies, 2013- 2014: Three Biosimilar MAbs on Sale
3.2 The World Market for Biosimilar MAbs: An Overarching Revenue Forecast, 2014-2025
3.3 The World Market for Biosimilar MAbs by Compound: Revenue and Market Share Predictions, 2019 and 2025
3.4 The World Market for Biosimilar MAbs by Compound: Revenue Forecasts, 2014-2025
3.4.1 Will Biosimilar Versions of Monoclonal Antibodies Capture a Large Proportion of the Market?
3.4.2 Biosimilar Infliximab: High Growth Expected
3.4.2.1 Biosimilar Infliximab: Revenue Forecast, 2015-2025
3.4.3 Biosimilar Rituximab: With Many Compounds Under Development, Will Sales Growth be Driven or Restrained?
3.4.3.1 Biosimilar Rituximab: Revenue Forecast, 2015-2025
3.4.4 Biosimilar Abciximab: Low Market Incentive Means Few Compounds in Development
3.4.4.1 Biosimilar Abciximab: Revenue Forecast, 2015-2025
3.4.5 Biosimilar Trastuzumab: The 4th Biosimilar MAb to Enter the Market
3.4.5.1 Biosimilar Trastuzumab: Revenue Forecast, 2015-2025
3.4.6 Biosimilar Adalimumab: Great Incentive to Develop Biosimilar Versions of the Leading Drug of 2013 & 2014
3.4.6.1 Biosimilar Adalimumab: Revenue Forecast, 2015-2025
3.4.7 Biosimilar Bevacizumab: Will Late Entry to the Market Restrict Revenue Generation?
3.4.7.1 Biosimilar Bevacizumab: Revenue Forecast, 2015-2025
3.5 Large Market Potential to Drive Growth to 2025
3.6 What Will Restrain Expansion of the Biosimilar MAbs Market Between 2013 and 2025?
4. Promising Biosimilar MAb Products and Their Predicted Future Successes, 2015-2025
4.1 Biosimilar Versions on the Market: Remsima Dominated in 2013
4.1.1 Celltrion’s Remsima / Hospira’s Inflectra / Egis’ Flammegis (infliximab): The First Official Biosimilar Monoclonal Antibody
4.1.2 Dr. Reddy’s Reditux (rituximab): Are US and EU Approval Expected?
4.1.3 Isu Abxis’ Clotinab (abciximab): The First Biosimilar Monoclonal Antibody?
4.1.4 Instas Pharmaceuticals’ Mabtas (Rituximab)
4.1.5 Reliance Life Sciences’ AbcixiRel (abciximab)
4.1.6 Probiomed’s Kikuzubam (rituximab): Registration Revoked, Reports Suggest
4.2 Biosimilar Versions on the Market and Promising Compounds in the R&D Pipeline: Revenue Forecasts, 2015-2025
4.2.1 Celltrion’s Remsima / Hospira’s Inflectra / Egis’ Flammegis (infliximab): Revenue Forecast, 2015-2025
4.2.2 Epirus Biopharmaceuticals’ Infimab (infliximab): Revenue Forecast, 2014-2025
4.2.3 Dr. Reddy’s Reditux (rituximab): Revenue Forecast, 2015-2025
4.2.4 Intas Pharmaceuticals’ Mabtas (rituximab): Revenue Forecast, 2015-2025
4.2.5 BIOCAD’s AcellBia (rituximab): Revenue Forecast, 2015-2025
4.2.6 Boehringer Ingelheim’s BI695500 (rituximab): Revenue Forecast, 2015-2025
4.2.7 Celltrion’s CT-P10 (rituximab): Revenue Forecast, 2015-2025
4.2.8 Isu Abxis’ Clotinab (abciximab): Revenue Forecast, 2015-2025
4.2.9 Reliance Life Sciences’ AbcixiRel (abciximab): Revenue Forecast, 2015-2025
4.2.10 Biocon and Mylan’s CANMAb/Hertraz (trastuzumab): Revenue Forecast, 2015-2025
4.2.11 Celltrion’s Herzuma (trastuzumab): Revenue Forecast, 2015-2025
4.2.12 BIOCAD’s BCD-022 (trastuzumab): Revenue Forecast, 2015-2025
4.2.13 Boehringer Ingelheim’s BI695501 (adalimumab): Revenue Forecast, 2015-2025
4.2.14 Fujifilm Kyowa Kirin Biologics’ FKB327 (adalimumab): Revenue Forecast, 2015-2025
4.2.15 BIOCAD’s BCD-021 (bevacizumab): Revenue Forecast, 2015-2025
4.2.16 Fujifilm Kyowa Kirin Biologics’ FKB238: Revenue Forecast, 2015-2025
5. Leading National Markets for Biosimilar Monoclonal Antibodies, 2015-2025
5.1 What Were the Leading National Markets for Biosimilar Monoclonal Antibody Development in 2013?
5.2 What Were the Leading National Markets for Sales of Biosimilar Monoclonal Antibodies in 2013?
5.3 Which Markets Will Grow Fastest to 2025?
5.4 Market Shares of the Leading National Markets: All Set to Change, 2015-2025
5.5 South Korea: The World’s Leading Nation for Biosimilar MAbs
5.5.1 KFDA Introduced Biosimilar Guidelines in 2009
5.5.2 Significant Investment in Biosimilars in South Korea
5.5.3 Outlook for the South Korean Biosimilar MAb Market, 2014-2025
5.6 The Outlook for Monoclonal Antibody Biosimilars in China, 2015-2025
5.6.1 China to Release Formal Biosimilar Development Guidelines
5.6.2 China: Becoming the World’s Leading Market for Biosimilar MAbs
5.7 Brazil: The Third Leading Country in the 2013 Biosimilar MAb Market, But What Does The Future Hold?
5.7.1 ANVISA’s Biosimilar Regulations Are Similar to the EMA’s
5.7.2 Outlook for Monoclonal Antibody Biosimilars in Brazil, 2015-2025
5.8 Outlook for Monoclonal Antibody Biosimilars in India, 2015-2025
5.8.1 India Releases New Biosimilar Development Guidelines
5.8.2 Indian Biosimilars Submarket Forecast 2015-2025
5.9 The Outlook for Biosimilar MAbs in the US, 2015-2025
5.9.1 When Are the Final FDA Biosimilar Guidelines Expected?
5.9.2 Legal Challenges for Biosimilars in the US
5.9.3 State Regulation of Biosimilar Substitution
5.9.4 The US Biosimilar MAb Market: Revenue Forecast, 2015-2025
5.10 The Outlook for Monoclonal Antibody Biosimilars in Japan 2015-2025
5.10.1 Regulatory Processes for Biosimilars in Japan
5.10.2 Regulations for Naming Biosimilars
5.10.3 Biosimilar MAbs to be Launched in Japan in 2016
5.10.4 Japanese Biosimilar Submarket Forecast 2015-2025
5.11 The Outlook for Monoclonal Antibody Biosimilars in the EU, 2015-2025
5.11.1 The EU Led the World in Biosimilar Regulation
5.11.2 Updating Biosimilar Regulation: Guidelines for the Specific Approval of Biosimilar MAbs
5.11.3 EMA Simplifies Biosimilar Development in the EU
5.11.4 Biosimilar MAbs in the EU5 Countries: Revenue Forecasts, 2015-2025
5.11.5 Germany: Set to Become the Largest National Market for Biosimilar MAbs in the EU
5.11.6 France: Will the Uptake of Biosimilar MAbs Be Restricted?
5.11.7 UK: Drug Uptake Will Be High
5.11.8 Italy: Healthcare Spending Cuts Will Drive Growth
5.11.9 Spain: High Biosimilar MAb Discounts Expected
5.12 The Outlook for Monoclonal Antibody Biosimilars in Russia, 2015-2025
5.12.1 No Specific Biosimilar Legislation Exists in Russia, 2014
5.12.2 Russian Government Investing in Development of Biosimilars
5.12.3 Russian Biosimilar MAb Revenue Forecast 2015-2025
6. Leading Companies for Developing and Producing Biosimilar MAbs
6.1 Prominent Companies in the Biosimilar Monoclonal Antibodies Industry, 2014
6.2 Collaboration in Biosimilar MAb Development
6.3 BioXpress: 16 Compounds in the R&D Pipeline
6.4 Celltrion: One Compound on the Market and Two in Phase III of Development, and Others Wait In The Wings
6.5 Harvest Moon: Six Compounds Under Development
6.6 Genor Biopharma: Five Compounds in Development
6.7 Mabion: Poland’s Leading Biosimilar MAb Developer
6.8 Gene Techno Science: Three Compounds Under Development
6.9 India’s Biocon: A Quiet Competitor
6.10 Pfizer: Entering the Biosimilar MAbs Industry and Market
6.11 BIOCAD: Company Based in Russia
6.12 Big Pharma and the Biosimilar MAbs Market
7. Qualitative Analyses of the Biosimilar MAbs Market, 2015-2025
7.1 Strengths and Weaknesses of the Biosimilar Monoclonal Antibody Market, 2014
7.1.1 Worldwide Demand for More-Affordable Therapies Underpins that Market
7.1.2 Complexity of Protein Molecules Gives Technical Challenges
7.2 Opportunities and Threats Facing the Biosimilar Monoclonal Antibody Market, 2015-2025
7.2.1 A Well-Stocked Pipeline in the Face of Approaching Patent Expiries: Opportunities for Market Expansion
7.2.2 Competition and Lack of Confidence: Threats to Market Penetration?
7.2.2.1 Biobetters as a Threat to Biosimilars
7.3 Social, Technological, Economic and Political Forces Influencing the Biosimilar Monoclonal Antibodies Market (STEP Analysis) 2015-2025
7.3.1 Social Factors: Driving or Restraining the Market?
7.3.2 Advances in Technology: Producing Biosimilar MAbs Cheaply and Easily
7.3.3 Economic Pressures Raise Demand for Biosimilar MAbs
7.3.4 Political Issues: Stringent Regulations Hurdles to Market Entry
8. Research Interviews from Our Survey
8.1 Interview with Bruce Burnett
8.1.1 On Regulations for and Testing of Biosimilars
8.1.2 On Drivers and Restraints for Biosimilar MAbs
8.1.3 Biosimilars and Immunogenicity
8.1.4 On Biosimilars and Research
8.2 Interview with Dr Corrine SinQuee-Brown, The Cancer Center Bahamas
8.2.1 On Biosimilar MAbs in The Bahamas
8.2.2 On Drivers and Restraints for Biosimilar MAbs
8.3 Interview with Dr Xing Wang, President of Array Bridge
8.3.1 On Challenges Surrounding the Development of Biosimilar MAbs
8.3.2 On the Services Offered by Array Bridge
8.3.3 On the Demand for Biosimilar MAbs
8.3.4 On Factors Determining the Success of Biosimilar MAbs
8.3.5 On Regulatory Approval of Biosimilar MAbs: The US vs. the EU
8.4 Interview With Dr Terence Ryan, SVP, iBio
8.4.1 iBio and its Biosimilar Pipeline, 2013
8.4.2 The iBioLaunch Platform
8.4.3 Differences Between Developing Biosimilar and Biologics
8.4.4 Product Differentiation in the Biosimilar Market
8.4.5 Biosimilars and Immunogenicity
8.4.6 Challenges in Developing Biosimilars for the US Market
9. Conclusions from the Research and Analysis
9.1 Biosimilar Monoclonal Antibodies: World Market, 2015-2025
9.2 The Future of Top Compounds in Development and Testing
9.3 Leading National Markets for Biosimilar Monoclonal Antibodies, 2015-2025
9.4 Leading Companies in the Industry
9.5 Trends in the Industry and Market
9.5.1 Economic Pressures Stimulate Demand for Therapeutic MAbs
9.5.2 Patent Expiries of Several Blockbuster MAbs Are Approaching, Creating Large Opportunities for Biosimilars
9.5.3 Complexity of the Molecules Make Production Challenging
9.5.4 Doctor and Patient Doubt Regarding Interchangeability Will Restrict Uptake
9.5.5 Do Biobetters Pose a Threat?
List of Tables
Table 1.1 Submarket Forecasts of Biosimilar MAbs, 2014-2025
Table 1.2 Currency Exchange Rates: Average Exchange Rate to USD
Table 2.1 Classification of Monoclonal Antibodies
Table 2.2 Murine Monoclonal Antibodies on the Market, 2013
Table 2.3 Chimeric Monoclonal Antibodies on the Market, 2013
Table 2.4 Humanised Monoclonal Antibodies on the Market, 2013
Table 2.5 Fully Human Monoclonal Antibodies on the Market, 2013
Table 2.6 Top 10 Prescription Drugs by Revenue ($bn), 2013
Table 3.1 The Biosimilar Monoclonal Antibody Market by Compound: Revenue ($m) and Market Share (%), 2013
Table 3.2 Biosimilar MAb World Market: Revenue Forecast ($m), 2014-2025
Table 3.3 The World Market for Biosimilar MAbs: Revenues ($m) and Market Shares (%) by Compound, 2013, 2019 and 2025
Table 3.4 Prominent Originator Biologic Products: EU and US Patent Expiry Dates
Table 3.5 Biosimilar MAbs: World Revenue Forecasts ($m) by Molecule, 2014-2025
Table 3.6 Biosimilar Infliximab: Compounds in the R&D Pipeline, 2014
Table 3.7 Biosimilar Infliximab: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 3.8 Biosimilar Rituximab: Compounds in the Pipeline, 2014
Table 3.9 Biosimilar Rituximab: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 3.10 Biosimilar Abciximab: Compounds in the Pipeline, 2014
Table 3.11 Biosimilar Abciximab: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 3.12 Biosimilar Trastuzumab: Compounds in the Pipeline, 2014
Table 3.13 Biosimilar Trastuzumab: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 3.14 Biosimilar Adalimumab: Compounds in Development, 2014
Table 3.15 Biosimilar Adalimumab: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 3.16 Biosimilar Bevacizumab: Compounds in the Pipeline, 2014
Table 3.17 Biosimilar Bevacizumab: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.1 Biosimilar MAb Versions on the Market: Revenues ($m) and Market Shares (%), 2013
Table 4.2 Biosimilar Versions on the Market and in the Pipeline: Revenue Forecasts ($m), 2014-2025
Table 4.3 Celltrion’s Remsima / Hospira’s Inflectra / Egis’ Flammegis (infliximab): Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.4 Epirus Biopharmaceuticals' Infimab: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.5 Dr. Reddy’s Reditux: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.6 Intas Pharmaceuticals’ Mabtas: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.7 BIOCAD’s AcellBia: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.8 Boehringer Ingelheim's BI695500: Revenue Forecast, 2014-2025
Table 4.9 Celltrion's CT-P10: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.10 Isu Abxis' Clotinab: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.11 Reliance Life Sciences’ AbcixiRel: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.12 CANMAb/Hertraz: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.13 Celltrion's Herzuma: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.14 BIOCAD's BCD-022: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.15 Boehringer Ingelheim's BI695501: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.16 Fujifilm Kyowa Kirin Biologics' FKB327: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.17 BIOCAD’s BCD-021: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.18 Fujifilm Kyowa Kirin Biologics' FKB238: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 5.1 Prominent Companies with 2+ Biosimilar MAbs in Development and Their Country of Origin, 2013
Table 5.2 The Biosimilar MAb Market by Country: Revenues ($m) and Market Shares (%), 2013
Table 5.3 The Biosimilar MAb Market by Country: Grouped Revenue Forecasts ($m), 2014-2025
Table 5.4 The Biosimilar MAb Market: National Market Shares (%), 2013-2025
Table 5.5 The South Korean Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2014-2025
Table 5.6 The Chinese Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2014-2025
Table 5.7 The Brazilian Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2014-2025
Table 5.8 The Indian Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2014-2025
Table 5.9 The US Biosimilar MAb Market: Revenue ($m) and Annual Growth (%) Forecast, 2014-2025
Table 5.10 The Japanese Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2014-2025
Table 5.11 EU5 Biosimilar MAb Markets: Overall Revenue ($m), Annual Growth (%) and CAGR (%) Forecasts by Country, 2014-2025
Table 5.12 The German Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2014-2025
Table 5.13 The French Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2014-2025
Table 5.14 The UK Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2014-2025
Table 5.15 The Italian Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2014-2025
Table 5.16 The Spanish Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2014-2025
Table 5.17 The Russian Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2014-2025
Table 6.1 Companies in the Biosimilar MAb Industry by Number of Compounds in Development, 2014
Table 6.2 Selected Collaborations for Biosimilar MAb Development, 2009-2014
Table 6.3 BioXpress: Compounds in the Pipeline, 2014
Table 6.4 Tests Carried Out By BioXpress During Biosimilar MAb Development, with Objectives
Table 6.5 Compounds in Celltrion’s Pipeline: Compound Name, Generic Name, Development Stage and Anticipated Year of Approval, 2013
Table 6.6 Genor Biopharma: Biosimilar MAbs Pipeline, 2014
Table 6.7 Mabion: Compounds in the Pipeline and Their Development Stage, 2014
Table 6.8 Gene Techno Science: Revenue and Gross Profit ($m), Year Ended March 2012 and 2013
Table 6.9 Biocon: Compounds in the Pipeline and Their Stage of Development, 2014
Table 6.10 Pfizer: Compounds in the Pipeline and Their Stage of Development, 2013
Table 6.11 BIOCAD: Compounds in the Pipeline and Their Stage of Development, 2013
Table 6.12 Big Pharma's Positions in the Biosimilar MAb Industry, 2013
Table 7.1 Strengths and Weaknesses of the Biosimilar MAb Market, 2015
Table 7.2 Opportunities and Threats Facing the Biosimilar MAb Market, 2015-2025
Table 7.3 Social, Technological, Economic and Political Factors Influencing the Biosimilar MAb Market (STEP Analysis), 2015-2025
List of Figures
Figure 1.1 Selected Biosimilar MAbs: Main Compound Classes, 2014
Figure 2.1 Structure of an Antibody
Figure 3.1 The Biosimilar Monoclonal Antibody Market by Compound: Market Share (%), 2013
Figure 3.2 The World Market for Biosimilar MAbs: Revenue Forecast ($m), 2014-2025
Figure 3.3 The Biosimilar MAb Market: Market Share (%) by Compound, 2019
Figure 3.4 The Biosimilar MAb Market: Market Share (%) by Compound, 2025
Figure 3.5 Biosimilar Infliximab: Revenue Forecast ($m), 2014-2025
Figure 3.6 Biosimilar Rituximab: Revenue Forecast ($m), 2014-2025
Figure 3.7 Biosimilar Abciximab: Revenue Forecast ($m), 2014-2025
Figure 3.8 Biosimilar Trastuzumab: Revenue Forecast ($m), 2014-2025
Figure 3.9 Biosimilar Adalimumab: Revenue Forecast ($m), 2014-2025
Figure 3.10 Biosimilar Bevacizumab: Revenue Forecast ($m), 2014-2025
Figure 3.11 Biosimilar MAbs: Market Drivers and Restraints, 2014-2025
Figure 4.1 Biosimilar MAb Versions on the Market: Market Share (%), 2013
Figure 4.2 Biosimilar MAb Versions on the Market and in the Pipeline: Market Shares (%), 2019
Figure 4.3 Biosimilar MAb Versions on the Market and in the Pipeline: Market Shares (%), 2025
Figure 4.4 Celltrion’s Remsima / Hospira’s Inflectra / Egis’ Flammegis (infliximab): Revenue Forecast ($m), 2014-2025
Figure 4.5 Epirus Biopharmaceuticals' Infimab: Revenue Forecast ($m), 2014-2025
Figure 4.6 Dr. Reddy’s Reditux: Revenue Forecast, 2014-2025
Figure 4.7 Intas Pharmaceuticals’ Mabtas Revenue Forecast ($m), 2014-2025
Figure 4.8 BIOCAD’s AcellBia: Revenue Forecast ($m), 2014-2025
Figure 4.9 Boehringer Ingelheim's BI695500: Revenue Forecast, 2014-2025
Figure 4.10 Celltrion's CT-P10: Revenue Forecast ($m), 2014-2025
Figure 4.11 Isu Abxis' Clotinab: Revenue Forecast ($m), 2014-2025
Figure 4.12 Reliance Life Sciences' AbcixiRel: Revenue Forecast ($m), 2014-2025
Figure 4.13 CANMAb/Hertraz: Revenue Forecast ($m), 2014-2025
Figure 4.14 Celltrion's Herzuma: Revenue Forecast, 2014-2025
Figure 4.15 BIOCAD's BCD-022: Revenue Forecast ($m), 2014-2025
Figure 4.16 Boehringer Ingelheim's BI695501: Revenue Forecast ($m), 2014-2025
Figure 4.17 Fujifilm Kyowa Kirin Biologics' FKB327: Revenue Forecast ($m), 2014-2025
Figure 4.18 BIOCAD’s BCD-021 Revenue Forecast ($m), 2014-2025
Figure 4.19 Fujifilm Kyowa Kirin Biologics' bevacizumab: Revenue Forecast ($m), 2014-2025
Figure 5.1 Geographical Distribution (%) of Prominent Compounds under Development, 2014
Figure 5.2 The Biosimilar MAb Market by Country: Market Shares (%) of Revenue, 2014
Figure 5.3 The Biosimilar MAb Market: National Submarket Shares (%), 2019
Figure 5.4 The Biosimilar MAb Market: National Submarket Shares (%), 2025
Figure 5.5 The South Korean Biosimilar MAb Market: Revenue Forecast ($m), 2014-2025
Figure 5.6 The Chinese Biosimilar MAb Market: Revenue Forecast ($m), 2014-2025
Figure 5.7 The Brazilian Biosimilar MAb Market: Revenue Forecast ($m), 2014-2025
Figure 5.8 The Indian Biosimilar MAb Market: Revenue Forecast ($m), 2014-2025
Figure 5.9 FDA Biosimilar Guidelines: Key Points
Figure 5.10 Biosimilar MAbs in the US: Revenue Forecast ($m), 2014-2025
Figure 5.11 The Japanese Biosimilar MAb Market: Revenue Forecast ($m), 2014-2025
Figure 5.12 The EU5 Biosimilar MAb Market: Grouped Revenue Forecast ($m), 2014-2025
Figure 5.13 The EU5 Biosimilar MAb Market: Revenue Forecasts ($m) by Country, 2014-2025
Figure 5.14 The German Biosimilar MAb Market: Revenue Forecast ($m), 2014-2025
Figure 5.15 The French Biosimilar MAb Market: Revenue Forecast ($m), 2014-2025
Figure 5.16 The UK Biosimilar MAb Market: Revenue Forecast ($m), 2014-2025
Figure 5.17 The Italian Biosimilar MAb Market: Revenue Forecast ($m), 2014-2025
Figure 5.18 The Spanish Biosimilar MAb Market: Revenue Forecast ($m), 2014-2025
Figure 5.19 The Russian Biosimilar MAb Market: Revenue Forecast ($m), 2014-2025
Figure 6.1 Prominent Companies in the Biosimilar MAb Industry: Share (%) of the Pipeline, 2014
Figure 9.1 Prominent Compounds in the Biosimilar MAb Market: Comparison of Revenues ($m), 2013, 2019 and 2025
Figure 9.2 Promising Versions of Biosimilar MAbs: Comparison of Revenues ($m), 2013, 2019 and 2025
Figure 9.3 Leading National Markets: Revenues ($m), 2013, 2019 and 2025
Figure 9.4 Prominent Companies in the Biosimilar MAb Industry: Number of Products in the Pipeline, 2013
|
현재위치 : 
